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Edited by Peter BrzezinskiAbstract 11b-Hydroxysteroid dehydrogenase type 1 is a
homodimer where the carboxyl terminus of one subunit covers
the active site of the dimer partner. Based on the crystal struc-
ture with CHAPS, the carboxyl terminal tyrosine 280 (Y280)
has been postulated to interact with the substrate/inhibitor at
the binding pocket of the dimer partner. However, the co-crystal
structure with carbenoxolone argues against this role. To clarify
and reconcile these ﬁndings, here we report our mutagenesis data
and demonstrate that Y280 is not involved in substrate binding
but rather plays a selective role in inhibitor binding. The involve-
ment of Y280 in inhibitor binding depends on the inhibitor chem-
ical structure. While Y280 is not involved in the binding of
carbenoxolone, it is critical for the binding of glycyrrhetinic acid.
 2007 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Carbenoxolone; Glycyrrhetinic acid1. Introduction
Two isozymes of 11b-hydroxysteroid dehydrogenase, type 1
and type 2 (11b-HSD1 and 11b-HSD2, respectively), regulate
tissue speciﬁc glucocorticoid action [1]. In intact cells and
in vivo, 11b-HSD1 is predominantly a reductase that converts
inert cortisone or 11-dehydrocorticosterone (11-DHC) to ac-
tive cortisol or corticosterone [2,3]. 11b-HSD2 is a dehydro-
genase and catalyzes the reverse reaction [1]. 11b-HSD1 is a
34-kDa protein localized in the endoplasmic reticulum (ER)
[4,5], with a short N-terminal transmembrane domain anchor-
ing the enzyme to the ER membrane and the rest of the enzyme
in the ER lumen [6,7]. Local production of cortisol or cortico-
sterone by 11b-HSD1 is an important step in the glucocorti-
coid receptor mediated physiological eﬀects [8]. 11b-HSD1,
primarily expressed in liver, adipose tissue and brain, playsAbbreviations: 11b-HSD1, 11b-hydroxysteroid dehydrogenase type 1;
11-DHC, 11-dehydrocorticosterone; CBX, carbenoxolone; CHAPS, 3-
[(3-cholamidopropyl)-dimethylammonio]-1-propane sulfonate; GE,
glycyrrhetinic acid
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[1]. Mice lacking 11b-HSD1 are resistant to diet-induced obes-
ity and insulin resistance [9–11]. When overexpressed in adi-
pose tissue, 11b-HSD1 induced obesity, insulin resistance
and other features of the metabolic syndrome [12]. These ﬁnd-
ings suggest that 11b-HSD1 plays a critical role in glucocorti-
coid induced metabolic eﬀects and is an attractive therapeutic
target for obesity and type 2 diabetes.
When puriﬁed from tissues or recombinant expression sys-
tems, 11b-HSD1 has both reductase and dehydrogenase activ-
ities [13,14], and it exists as a homodimer [15]. The resolved
crystal structures of the 11b-HSD1 enzymes from guinea pig,
human and mouse support this notion [16–18]. The overall
organization of the homodimer in the three diﬀerent species
is similar, with the C-terminal helix of one subunit facing the
substrate binding pocket of the dimer partner. In particular,
among the several residues that directly cap the active site of
the dimer partner, one tyrosine residue (Y280 in human) has
been shown to face the active site of the dimer partner [17].
Y280 is very likely to be involved in stabilizing the substrate
since it is in close distance/contact. However, the C-terminal
tail of 11b-HSD1 (ca. 15 residues) appears to have some de-
gree of ﬂexibility and is often not well resolved in the crystal
structure (unpublished data), which increases the diﬃculty to
conclusively deﬁne the distance of Y280 to the substrate or
inhibitor at the active site of the dimer partner. In fact, the
co-crystal structure of 11b-HSD1 with carbenoxolone (CBX)
deposited by Oppermann et al. at Protein Data Bank (PDB)
indicates that Y280 is not involved in the interaction with
CBX at the active site of the dimer partner (PDB code:
2BEL.pdb). To reconcile the ambiguous results generated from
the crystallographic studies, here we present mutagenesis stud-
ies to investigate the contribution of this residue to the binding
pocket of the dimer partner.2. Materials and methods
An N-terminally deleted version of human 11b-HSD1 (aa 24–292)
with an N-terminal 6-histidine tag was expressed in E. coli as described
previously [19]. The expression vector was used as a template to gener-
ate mutations in the key tyrosine residue Y280 using the QuickChange
site-directed mutagenesis kit (Stratagene). Mutations were conﬁrmed
by sequencing. The expression vectors for the wild-type and mutant
forms of human 11b-HSD1 were transformed into E. coli BL21
(DE3) cells for fermentation to produce recombinant proteins. Theation of European Biochemical Societies.
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pcDNA3.1 for transfection studies in Chinese hamster ovary (CHO)
cells. For protein puriﬁcation, the cell paste from the fermentation
was suspended and homogenized in 20 mM Tris–HCl (pH 8.0) con-
taining 5% glycerol, 5 mM benzamidine, 150 mM NaCl, and 5 mM
imidazole with 1% triton X-100 added after homogenization. The
homogenate was ﬁltered using a 0.45 lm membrane. Protein was
puriﬁed using a Ni-NTA column followed by gel ﬁltration chroma-
tography with a Superdex-200 column [19]. Protein purity was con-
ﬁrmed by gel electrophoresis under reduced condition and the ﬁnal
protein preparation was stored at 80 C in 20 mM Tris–HCl (pH
8.0), 200 mM NaCl, 5% glycerol, 2 mM EDTA, and 0.1% Triton
X-100.
Enzyme reactions were run at room temperature in the presence of
various cortisone concentrations ranging 0.2–10 lM, 300 lM of coen-
zyme NADPH, and 100 nM puriﬁed enzyme. Cortisol formed was
quantiﬁed on a Dionex HPLC instrument as described previously
[19]. The initial velocity was determined in the linear range of cortisol
formation. Km values were calculated with Graﬁt 5.0.3 software
(Erithacus Software, Horley Surrey, UK) using a ﬁrst-order rate equa-
tion [19]. CHO cells were used for transient transfection. Transfected
cells were washed three times with 50 mMHEPES buﬀer (pH 7.4) [con-
taining 120 mM NaCl, 1.85 mM CaCl2, 1.33 mMMgSO4, and 4.4 mM
KCl]. Whole cell enzymatic assay was run with 100 nM cortisone in the
same buﬀer at 37 C for 1 h. The cortisol produced by the transfected
cells was determined using a Cortisol Enzyme Immunoassay Kit (As-
say Designs, Inc., Ann Arbor, MI). Lysates from the same cells were
subjected to Western blotting to measure protein expression levels
using polyclonal antibodies against human 11b-HSD1 [19].3. Results and discussion
3.1. Structural analysis of the role of Y280 in substrate and
inhibitor binding
Human 11b-HSD1 has been co-crystallized in the presence
of the cofactor NADP+ and the steroidal detergent CHAPS
[17]. In addition, the co-crystal structure with carbenoxolone
(CBX) has been resolved by Oppermann and colleagues
(PDB code: 2BEL.pdb). Both CBX and glycyrrhetinic acid
(GE) are licorice derivatives that inhibit 11b-HSD1 [20,21].
CBX is the hemisuccinate ester of GE but the nature of their
binding to the 11b-HSD1 active site may diﬀer due to the sig-
niﬁcant structural diﬀerences [19]. The co-crystal structure of
11b-HSD1 with GE has not been reported.
Based on the crystal structure of human 11b-HSD1 (residue
24–292) with a CHAPS molecule at the active site (PDB code:Fig. 1. Substrate and cofactor binding site of 11b-HSD1. (A) CHAPS co-c
green and the dimer partner in purple. CHAPS and NADP+ are shown in sp
for sulfur, and cyan and grey for carbon for CHAPS and NADP+, respectiv
molecular surface representation. (B) CBX co-crystal structure (PDB code: 2B
dimer partner (in purple) ends at residue 277.1XU9.pdb) [17], the Y280 residue at the C-terminal tail is with-
in a distance of van der Waals interaction from the CHAPS
molecule at the active site of the dimer partner (Fig. 1A), sug-
gesting that Y280 may play an active role in the binding and/or
stabilization of the substrate or inhibitor. However, the co-
crystal structure with CBX (PDB code: 2BEL.pdb) failed to
show such an interaction and Y280 is not within an interaction
distance with the active site of the dimer partner. Rather, the
C-terminal tail is apparently very mobile (Fig. 1B). The four
protein molecules end with residues 268, 277, 271, and 277,
respectively, although the protein construct contains residues
26–284. The fact that they do not see Y280 in the CBX co-crys-
tal structure is likely due to the conformational ﬂexibility. This
observation suggests that CBX has no interaction with Y280.
Our repeated attempts to resolve the co-crystal structure of
11b-HSD1 with GE only led to a resolution at 3.2 A˚ (data
not shown). In this structure, Y280 is in the vicinity of GE
but its side chain has very little density, suggesting that the side
chain of this residue may be mobile. However, the resolution
of this crystal structure is not high enough to well deﬁne the
role of Y280 in GE binding. In summary, the ﬁndings based
on crystal structures have generated ambiguous results regard-
ing the role of Y280 in the substrate/inhibitor binding by the
dimer partner.
3.2. Biochemical determination of the role of Y280 in substrate
and inhibitor binding
To resolve the ambiguous results with crystal structures, we
relied on ﬁndings from site-directed mutagenesis studies to
determine the role of Y280 in substrate and inhibitor binding.
Three mutants were generated by replacing the tyrosine residue
with alanine (Y280A), serine (Y280S) and phenylalanine
(Y280F), respectively. Y280A is useful in understanding the
overall importance of the Y280 side chain and Y280F helps
identify the role of the hydroxyl group on the side chain. Since
the rodent and human enzymes use diﬀerent substrates and the
rodent residue corresponding to Y280 is a serine, Y280S was
made to explore substrate speciﬁcity across diﬀerent species.
In addition, Y280S has a diﬀerent side chain but possesses
the hydroxyl group, oﬀering an alternative to address the po-
tential involvement of the hydroxyl group in substrate/inhibi-
tor interactions.rystal structure (PDB code: 1XU9.pdb), with one molecule colored in
heres. The color code is red for oxygen atom, blue for nitrogen, yellow
ely. Y280 from the C-terminal helix of the dimer partner is shown in
EL.pdb) with CBX in pink and NADP+ in grey. The C-terminus of the
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solved on a reduced SDS–PAGE gel (Fig. 2A). The Km values
were determined using three diﬀerent substrates: cortisone and
11-DHC for reductase activity and cortisol for dehydrogenase
activity. When assayed for reductase activity, the wild-type
and mutant enzymes exhibited similar Km values for either cor-
tisone or 11-DHC, although statistically signiﬁcant diﬀerences
between the absolute values were observed (Fig. 2B). These
data suggest that in contrast to what was implicated by the
crystal structure of human 11b-HSD1 with CHAPS as a ligand
[17], Y280 does not play an important role in either cortisone
or 11-DHC binding. The Km values for cortisol were deter-
mined to evaluate substrate binding for the dehydrogenase
activity. There were statistically signiﬁcant changes in the Km
values for cortisol using the mutants, with Y280A and
Y280F gaining slightly higher aﬃnity for cortisol while
Y280S losing onefold of aﬃnity (Fig. 2B). However, these
changes are not drastic and these data suggest that Y280 isFig. 2. (A) SDS–polyacrylamide gel electrophoresis (PAGE) of puriﬁed wild
type and mutant enzymes using three diﬀerent substrates. Cortisone and 11-D
used as a substrate for the dehydrogenase activity. Data are expressed as mean
**P < 0.01. (C) Comparison of Vmax values of the wild-type and mutant e
means ± S.D.; n = 3 for cortisone and 11-DHC; n = 2 for cortisol. *P < 0.05not critical for cortisol binding in the dehydrogenase reaction.
The mutations had drastic eﬀects on the Vmax value with cor-
tisol as substrate (Fig. 2C). Although some statistically signif-
icant diﬀerences in Vmax were observed with cortisone or 11-
DHC as substrate, the changes are small (Fig. 2C).
The reductase activities of the mutants were further charac-
terized in transiently transfected cells for their ability to con-
vert cortisone to cortisol. Consistent with the in vitro
ﬁndings, there was no diﬀerence observed in the cells’ ability
to convert cortisone to cortisol (Fig. 3A). Similar amount of
enzymes were expressed in the cells transfected with diﬀerent
constructs (Fig. 3B). These data demonstrate that signiﬁcant
structural changes at Y280 has very little eﬀect on substrate
binding, suggesting that Y280 plays no role in substrate bind-
ing at the active site of the dimer partner. In addition, the
residue corresponding to human Y280 in both mouse and rat
11b-HSD1 is a serine. The human and mouse enzymes have
comparable activities with cortisone or 11-DHC as substrates-type and mutant enzymes. (B) Comparison of Km values of the wild-
HC were used as substrates for the reductase activity, and cortisol was
s ± S.D.; n = 3 for cortisone and 11-DHC; n = 2 for cortisol. *P < 0.05;
nzymes using substrates as described in (B). Data are expressed as
; **P < 0.01.
Fig. 3. Enzymatic activities of the wild-type and mutant 11b-HSD1 enzymes in a cell-based assay. (A) CHO cells transiently expressing the wild-type
or mutant 11b-HSD1 enzymes were incubated with 100 nM cortisone at 37 C for 1 h, and the cortisol produced in the incubation buﬀer was
quantiﬁed as described in Section 2. Data are expressed as means ± S.D.; n = 3. (B) The same cells in the cell-based assay were harvested after the
cortisone incubation and cell lysates were prepared to determine the enzyme expression levels using Western blotting. Same amount of lysate was
loaded in each lane. Control represents the data from the cells transfected with the blank vector.
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substrates. These data suggest that Y280 is unlikely to play
an important role in substrate speciﬁcity.
3.3. Role of Y280 in inhibitor binding in vitro
To assess the potential role of Y280 in the binding of CBX
and GE, the IC50 values of the two common 11b-HSD1 inhib-
itors were determined. The substitution of Y280 with A, F or S
did not appear to have any signiﬁcant eﬀect on the IC50 value
of CBX (Fig. 4). These mutations on the side chain include
complete elimination of the side chain, removal of the hydro-
xyl group, and changing the side chain while maintaining the
hydroxyl group, respectively. Despite these changes, there
was no change in the aﬃnity of CBX for the enzyme
(Fig. 4). These data suggest that Y280 is dispensable for
CBX binding which is consistent with the deposited co-crystal
structure of 11b-HSD1 (PDB code: 2BEL.pdb). However, allFig. 4. Eﬀect of the mutations on the IC50 values of CBX and GE. The IC
determined and compared. Data are expressed as means ± S.D.; n = 3. *P <the three substitutions signiﬁcantly increased the IC50 value
for GE (Fig. 4), suggesting that the Y280 residue is critical
for GE binding. Interestingly, Y280A and Y280F mutations
caused drastic changes in the aﬃnity for GE. Y280S, which
maintains a hydroxyl group on the side chain, only increased
the IC50 value by onefold. Taken together, the eﬀect of the
mutations on the IC50 of CBX and GE suggest that Y280 is
only selectively involved in inhibitor binding at the active site
of the dimer partner. This phenomenon is consistent with the
mobile nature of the C-terminal tail of the enzyme. The con-
formation that brings Y280 close to the active site to interact
with an inhibitor is likely dependent on the chemical structure
of the inhibitor.
In conclusion, the Y280 residue in human 11b-HSD1 does
not play a role in substrate binding. It may be critical in inhib-
itor binding but this is highly dependent on the chemical struc-
ture of the inhibitor.50 values of CBX and GE for the wild-type and mutant enzymes were
0.05; **P < 0.01.
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